Fulgent Genetics raises FY25 EPS view to (35c) from (65c), consensus (55c)

Raises FY25 revenue view to $320M from $310M, consensus $310.68M. The company said, “Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company’s ongoing stock repurchase program or other expenditures outside the ordinary course of business, including M&A.”